Nantes, France

Cécile Boyer

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Chu Nantes, Ecole Nationale Veterinaire, National Institute of Health and Medical Research. Active years: 2020.


 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cécile Boyer: Innovator in Diabetes Treatment

Introduction

Cécile Boyer is a notable inventor based in Nantes, France. He has made significant contributions to the field of diabetes treatment through his innovative research and development of medical technologies. His work focuses on improving the lives of individuals suffering from type 1 diabetes.

Latest Patents

Cécile Boyer holds a patent for "Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes." This invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for treating type 1 diabetes. The patent also includes methods and kits designed to restore and maintain euglycemia in type 1 diabetic patients and those who are prediabetic.

Career Highlights

Throughout his career, Cécile Boyer has worked with esteemed institutions such as Ecole Nationale Vétérinaire and Chu Nantes. His experience in these organizations has allowed him to develop and refine his innovative ideas in the medical field.

Collaborations

Cécile Boyer has collaborated with notable colleagues, including Jean-Marie Bach and Mathilde Mosser. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Cécile Boyer is a pioneering inventor whose work in diabetes treatment showcases the potential of innovative medical solutions. His contributions are vital in the ongoing fight against type 1 diabetes, and his patent reflects a significant step forward in this important area of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…